Hanson Pharmaceuticals (03692): Innovative drug Amirac® successfully added two new indications to the new 2025 National Health Insurance Catalogue
According to Zhitong Finance App, Hanson Pharmaceuticals (03692) announced that the Group's innovative drug Amelot ® added two new indications successfully included in the new “National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalogue (2025)” (2025 National Health Insurance Catalogue), and that all indications of Saint Lorraine® and Hengmu® were included in the 2025 national medical insurance catalogue. The new version of the national catalogue will be officially implemented on January 1, 2026.
1. Two new indications approved for ametinib mesylate tablets (trade name: amirol ®) in March and April 2025 are included in the 2025 national health insurance catalogue: patients with EGFR exon 19 deficiency or exon 21 (L858R) replacement mutations in the II-IIIB stage who have previously undergone surgical resection treatment; treatment of adult non-small cell lung cancer (NSCLC) patients with EGFR exon 19 during or after platinum-containing chemotherapy; no disease progression during or after receiving platinum-containing chemoradiotherapy, and absence or appearance of EGFR exon 19 Treatment of adult patients with locally advanced, unresectable (stage III) NSCLC with substitution mutations in daughter 21 (L858R).
2. Both indications of pemoxatide injection (trade name: Saint Rolle ®) have been renewed and included in the 2025 national medical insurance catalogue: used to treat anemia caused by chronic kidney disease, including: 1. Adult non-dialysis patients not treated with erythropoiesis stimulants (ESA); 2. Adult dialysis patients receiving short-acting erythropoietin treatment.
3. Amitenofovir tablets (trade name: Hengmu®) were renewed and included in the 2025 national medical insurance catalogue for adult patients with chronic hepatitis B.
In addition, the Group's innovative drugs flumatinib mesylate tablets (trade name: Hausen Xinfu®), polyethylene glycol loxenatide injection (trade name: Fremei®), and inelizumab injection (trade name: Xinyue ®) are used for NMOSD and ametinib mesylate tablets (trade name: Ameil®) for the treatment of first-line and second-line NSCLC. Currently, they are all within the national medical insurance catalogue agreement period, and the agreement is valid until December 31, 2026; Morpholinidazole sodium chloride injection (trade name: Melinda®) has been included in category B of the national health insurance routine catalogue.